MedPath

A prospective observational study of nivolumab plus chemotherapy for advanced gastric cancer using CyberOncology (WJOG15922G)

Not Applicable
Recruiting
Conditions
nresectable advanced or recurrent gastric or esophagogastric junction cancer
Registration Number
JPRN-UMIN000049928
Lead Sponsor
West Japan Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1) Concomitant active malignancies within 3 years prior to registration 2) Active autoimmune disease 3) Requiring systemic corticosteroid or immunosuppressant within 14 days prior to registration 4) Active infection under treatment 5) Pregnant or lactating female 6) Uncontrolled psychiatry disease 7) History of serious allergic reactions 8) Judged inappropriate by the investigators

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath